Viewing Study NCT05482893


Ignite Creation Date: 2025-12-25 @ 1:12 AM
Ignite Modification Date: 2025-12-25 @ 11:22 PM
Study NCT ID: NCT05482893
Status: RECRUITING
Last Update Posted: 2025-11-04
First Post: 2022-07-25
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Sponsor: Phanes Therapeutics
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module